Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the third quarter ended September 30, 2024 and provided key business updates.

Author
Recent Posts

GlobeNewswire

GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates

Related Posts

iSTAR Medical’s MINIject® demonstrates significant sustained 5-year efficacy in treating glaucoma in STAR-GLOBAL trial

Actimed Therapeutics Appoints Shaun Claydon as Chief Financial Officer

Quadient Named a Leader in the SPARK Matrix™: Customer Communication Management Report for 2025

MYT Netherlands Parent B.V. (“Mytheresa”) and Richemont announce the successful completion of Mytheresa’s acquisition of YOOX NET-A-PORTER (“YNAP”)

Bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patients

Tarkett Participation increases the price offered in its public buy-out Offer- Tarkett’s Supervisory Board issues a favorable reasoned opinion based on the increased Offer price and the work of the independent expert

U.S. Dollar Slumps Amid Lingering Worries About Trump Tariffs

Latest Posts

Welcome Back!

Retrieve your password